Results 201 to 210 of about 683,284 (269)

Population‐Based Multi‐Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease

Advanced Science, EarlyView.
Psoriatic disease (PsD) is a chronic skin disease, with challenges in early risk stratification and drug development. Through gene‐level causal inference framework and expression level validation, combined with longitudinal cohort study, CDSN and PRSS8 have been identified as candidate biomarkers and therapeutic targets for PsD.
Tianxing Wu, Jialiang Luo, Haoyuan Qiu, Weijie Shao, Yueyang Lu, Meixuan Luo, Zhaofeng Lin, Yan Zhang, Libo Zhang, Hong Wang, Jia Zhou, Guangfeng Ruan, Peihua Cao, Daming Zuo   +13 more
wiley   +1 more source

Revisiting the impact of BRCA1 pathogenic variants on the aggressiveness of prostate cancer. [PDF]

JNCI Cancer Spectr
Sasagawa H, Narita S, Matsuda K, Kosaka T, Momozawa Y.   +4 more
europepmc   +1 more source

The significance of pelvis positron emission tomography and magnetic resonance tomography for surgical planning in patients with high risk prostate cancer

, 2019
М. Ш. Шихзадаев, М. I. Shkolnik, A. A. Stanjevskiy, О. А. Богомолов, А. Л. Долбов   +4 more
openalex   +2 more sources

PDIA3 Inhibition Facilitates Sensitivity of IKE‐Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy

Advanced Science, EarlyView.
In this manuscript, protein disulfide isomerase A3 (PDIA3) is identified as a key factor mediating the susceptibility of ferroptosis in GBM. Inhibition of PDIA3 enhances IKE or cystine starvation‐induced ferroptosis in GBM cells by resulting in the accumulation of lipid peroxidation and a reduction in GSH level.
Jie Zhang, Wei Wang, Xin Liu, Peifen Lu, Xinjing Liu, Qiucheng Nie, Siyuan Xin, Hong Li, Donglin Yu, Xinyue Zhang, Kailong Li, Xiaomin Han, Shuping Zhang, Wei Chong, Lili Sun, Wei Li, Tao Xin, Jin Jiao, Qiang Ma, Yiju Wei   +19 more
wiley   +1 more source

TDP2 drives immune evasion and metastatic progression in prostate cancer. [PDF]

PLoS One
Cao H, Pan A, Chen Y, Zheng F.
europepmc   +1 more source

CD169+ Macrophage‐Targeted Immunomodulator to Restore Phagocytic Function and Enhance Antigen Presentation for Lymphatic Metastasis Eradication

Advanced Science, EarlyView.
A CD169+ macrophage‐targeted immunomodulator (G‐LNP@S‐D) is developed to co‐deliver a SHP2 inhibitor and STING agonist, thereby restoring phagocytic function, enhancing antigen presentation by CD169+ macrophages, and promoting T cell priming to eradicate lymphatic metastasis.
Xiayun Chen, Lichong Lu, Yibin Liu, Ziqi Liang, Jianqiao Li, Zhouchuan Shao, Youzhi Tang, Jianhua Zou, Shiying Li, Xiaoyuan Chen   +9 more
wiley   +1 more source

Prostate cancer statistics, 2025. [PDF]

CA Cancer J Clin
Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL.   +5 more
europepmc   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Advanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
wiley   +1 more source

GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. [PDF]

Endocr Relat Cancer
Bera S, Gutgesell LC, Darden B, Sargis RM, Maienschein-Cline M, Gaber CE, Reizine NM, Vander Griend DJ, Vellky JE.   +8 more
europepmc   +1 more source

Frequency of Adenocarcinoma in Transrectal Ultrasound-guided Prostate Needle Biopsies in Men with Clinical Suspicion of Prostate Cancer and Raised Serum Prostate Specific Antigen

, 2013
Rahma Rashid, Muhammed Mubarak, Javed l. Kazi   +2 more
openalex   +1 more source